Eli Lilly's diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
said Mounjaro sales swelled more than 70% since the first quarter to $980 million. Almost all of that came from the U.S., and the company said significant demand was leading to delays in filling orders for some doses.Executives said Tuesday that they expect tight supplies will lead to some spot shortages of Ozempic through year’s end.is building a new manufacturing plant in North Carolina and expanding at another location there.
Separately, Novo said Tuesday that early results from a large, late-stage study of Wegovy showed that it cut the risk of serious heart problems by 20%. That was better than expected.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Soaring Sales of Diabetes Drug Mounjaro Propel Eli Lilly to New HeightsEli Lilly's diabetes treatment Mounjaro, known for its off-label use as a weight-loss drug, exceeded Wall Street's expectations by generating nearly $1 billion in sales during the second quarter. The drug's success reflects the growing demand for weight-loss treatments, prompting regulators to consider approving it for this purpose as well.
Lire la suite »
Eli Lilly Raises Forecasts with Diabetes Drug Mounjaro's Strong PerformancePharmaceutical company Eli Lilly has increased its forecasts after its diabetes drug Mounjaro delivers positive results, boosting the company's outlook.
Lire la suite »
Eli Lilly Hits Record High After Earnings, Mounjaro HypeEli Lilly's stock reaches a new high following strong earnings and positive market reactions. The company surpassed revenue and earnings estimates for the second quarter and raised its full-year guidance. Experts, including Jim Cramer, discuss the drugmaker's performance and its significant profit growth compared to the previous year.
Lire la suite »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Lire la suite »
Ozempic and Mounjaro makers sued by patient alleging ‘severe gastrointestinal issues'The medications are used to treat Type 2 diabetes and have become popular weight-loss drugs.
Lire la suite »
Patient Sues Ozempic and Mounjaro Makers Over Severe Gastrointestinal IssuesA patient from Louisiana has filed a lawsuit against Novo Nordisk, the maker of Ozempic, and Eli Lilly, the maker of Mounjaro, alleging that they failed to adequately warn about the potential adverse side effects of the medications, including the risk of gastroparesis.
Lire la suite »